Search research articles
Contact Us
Filters
Showing results (981-990 of 1,171) with videos related to
Page
of 118
Sort By:
The New England Journal of Medicine
|
October 29, 2010
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor
James E Butrynski, David R D'Adamo, Jason L Hornick, et al.
JCI Insight
|
September 10, 2021
Tie2 activation protects against prothrombotic endothelial dysfunction in COVID-19
Alec A Schmaier, Gabriel M Pajares Hurtado, Zachary J Manickas-Hill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2026
Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
Rana R McKay, Wanling Xie, Archana Ajmera, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 18, 2026
Regulation of the immune CD155-CD226-TIGIT axis by cyclin D-CDK4/6
Anne Fassl, Miriam Palacios Espinoza, Deborah Butter, et al.
JCO Precision Oncology
|
July 9, 2025
LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes
Sriram Anbil, Nicholas J Seewald, E Gabriela Chiorean, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 25, 2012
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors
Anthony W Tolcher, Wells A Messersmith, Stanislaw M Mikulski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 5, 2013
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer
Mark A Socinski, Jonathan Goldman, Iman El-Hariry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2020
Phase IB Study of Osimertinib in Combination with Navitoclax in <i>EGFR</i>-mutant NSCLC Following Resistance to Initial <i>EGFR</i> Therapy (ETCTN 9903)
Erin M Bertino, Ryan D Gentzler, Sarah Clifford, et al.
ESMO Open
|
March 11, 2026
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer
S Jacob, E L Mayer, N Kacik, et al.
Elife
|
November 14, 2018
Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
Mei Zeng, Nicholas P Kwiatkowski, Tinghu Zhang, et al.
Page
of 118
Search research articles
Search
Showing results (981-990 of 1,171) with videos related to
Sort By:
Page
of 118
The New England Journal of Medicine
|
October 29, 2010
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor
James E Butrynski, David R D'Adamo, Jason L Hornick, et al.
JCI Insight
|
September 10, 2021
Tie2 activation protects against prothrombotic endothelial dysfunction in COVID-19
Alec A Schmaier, Gabriel M Pajares Hurtado, Zachary J Manickas-Hill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2026
Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
Rana R McKay, Wanling Xie, Archana Ajmera, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 18, 2026
Regulation of the immune CD155-CD226-TIGIT axis by cyclin D-CDK4/6
Anne Fassl, Miriam Palacios Espinoza, Deborah Butter, et al.
JCO Precision Oncology
|
July 9, 2025
LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes
Sriram Anbil, Nicholas J Seewald, E Gabriela Chiorean, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 25, 2012
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors
Anthony W Tolcher, Wells A Messersmith, Stanislaw M Mikulski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 5, 2013
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer
Mark A Socinski, Jonathan Goldman, Iman El-Hariry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2020
Phase IB Study of Osimertinib in Combination with Navitoclax in <i>EGFR</i>-mutant NSCLC Following Resistance to Initial <i>EGFR</i> Therapy (ETCTN 9903)
Erin M Bertino, Ryan D Gentzler, Sarah Clifford, et al.
ESMO Open
|
March 11, 2026
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer
S Jacob, E L Mayer, N Kacik, et al.
Elife
|
November 14, 2018
Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
Mei Zeng, Nicholas P Kwiatkowski, Tinghu Zhang, et al.
Page
of 118